Non–Small Cell Lung Cancer Coverage from Every Angle
ABOUT
SECTIONS
JNCCN Spotlights
Videos
News
Medical Literature
CE Activities
Clinical Trials
For Your Patients
NCCN RESOURCES
NCCN Guidelines
®
NCCN Compendium
®
NCCN Templates
®
NCCN Guidelines for Patients®
360 HUB
Advanced Skin Cancers
CLL/MCL
Multiple Myeloma
Non–Small Cell Lung Cancer
Ovarian Cancer
JNCCN
Editor:
Gregory J. Riely, MD, PhD
Advertisement
Advertisement
Ongoing CE Activities
Improving Lung Cancer Care Through Understanding the Patient Experience
Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy
Implications of Recent Data Sets for the Current and Future Management of Lung Cancer
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Unlocking the Potential of Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: the Role of Checkpoint Inhibitors
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR
Applying the Latest Evidence in the Management of Early-Stage Non-Small Cell Lung Cancer
Targeted Therapy for Fusions
Key Presentations on Lung Cancer from Recent Major Conferences
JNCCN Spotlights
?
(NEW Update) Nivolumab in NSCLC
(UPDATE) Nivolumab in NSCLC
Repotrectinib for ROS1-Positive NSCLC
View More >
Advertisement
Resources
For your Patients
Copyright ©
2026
National Comprehensive Cancer Network, All Rights Reserved
Bots not welcome here